ScholarIQanswers from OpenAlex & ORCID
Erika Hamilton
ResearcherPublications, citations & collaboration network
Erika Hamilton is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Erika Hamilton have?
ScholarIQindexed works
Erika Hamilton has 844 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Erika Hamilton have?
ScholarIQcitation count
Erika Hamilton has 18,665 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Erika Hamilton?
ScholarIQh-index
Erika Hamilton has an h-index of 61 in OpenAlex.
What is the i10-index of Erika Hamilton?
ScholarIQi10-index
Erika Hamilton has an i10-index of 236 in OpenAlex.
What is the ORCID of Erika Hamilton?
ScholarIQorcid
The ORCID for Erika Hamilton is on the source record.
What is the OpenAlex record for Erika Hamilton?
ScholarIQopenalex
The OpenAlex for Erika Hamilton is on the source record.
What are the most-cited papers on Erika Hamilton?
ScholarIQmost cited works
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Rashmi K. Murthy, Sherene Loi, Alicia Okines, Elisavet Paplomata, Erika Hamilton, Sara A. Hurvitz, Nancy U. Lin, Virginia F. Borges, Vandana G. Abramson, Carey K. Anders, Philippe L. Bédard, Mafalda Oliveira, Erik Jakobsen, Thomas Bachelot, Shlomit Strulov Shachar, Volkmar Müller, Sofía Braga, François P. Duhoux, Richard Greil, David Cameron, Lisa A. Carey, Giuseppe Curigliano, Karen A. Gelmon, Gabriel N. Hortobágyi, Ian E. Krop, Sibylle Loibl, Mark D. Pegram, Dennis J. Slamon, Maria Corinna Palanca-Wessels, Luke Walker, Wentao Feng, Eric P. Winer
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Nancy U. Lin, Virginia F. Borges, Carey K. Anders, Rashmi K. Murthy, Elisavet Paplomata, Erika Hamilton, Sara A. Hurvitz, Sherene Loi, Alicia Okines, Vandana G. Abramson, Philippe L. Bédard, Mafalda Oliveira, Volkmar Müller, Amelia Zelnak, Michael P. DiGiovanna, Thomas Bachelot, A. Jo Chien, Ruth O’Regan, Andrew Wardley, Alison Conlin, David Cameron, Lisa A. Carey, Giuseppe Curigliano, Karen A. Gelmon, Sibylle Loibl, JoAl Mayor, Suzanne McGoldrick, Xuebei An, Eric P. Winer
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
Aditya Bardia, Sara M. Tolaney, Kevin Punie, Delphine Loirat, Mafalda Oliveira, Kevin Kalinsky, Amelia Zelnak, Philippe Aftimos, Florence Dalenc, Sagar Sardesai, Erika Hamilton, Priyanka Sharma, Sabela Recalde, Eva Ciruelos Gil, T Traina, Joyce O’Shaughnessy, Javier Cortés, Mu‐Hung Tsai, Linda T. Vahdat, Véronique Dièras, Lisa A. Carey, Hope S. Rugo, David M. Goldenberg, Q. Hong, Martin Olivo, Loretta M. Itri, Sara A. Hurvitz
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
Aditya Bardia, Ian E. Krop, Takahiro Kogawa, Dejan Juric, Anthony W. Tolcher, Erika Hamilton, Toru Mukohara, Aaron Lisberg, Toshio Shimizu, Alexander I. Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P. Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger‐Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric‐Bernstam